BiotechTube
Aldatu Biosciences

Aldatu Biosciences

Cambridge, United States· Est.
aldatubio.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $21.5M

Overview

Aldatu Biosciences is a private, US-based biotech founded in 2014, specializing in adaptive PCR diagnostics for infectious diseases. Its proprietary PANDAA technology platform addresses a critical challenge in molecular diagnostics by allowing real-time PCR assays to remain effective against evolving viral variants, thereby ensuring long-term assay integrity. The company's pipeline targets high-need areas including HIV drug resistance testing and pandemic preparedness for pathogens like SARS-CoV-2, Lassa virus, Ebola, and Crimean-Congo Hemorrhagic Fever virus. Operating as a public benefit corporation, Aldatu leverages grant funding, such as NIH SBIR awards, to advance its platform and expand its diagnostic product portfolio.

Infectious Disease

Technology Platform

Pan-Degenerate Amplification and Adaptation (PANDAA™) platform for adaptive PCR diagnostics that corrects for sequence diversity in target genomes, allowing detection in highly variable regions without assay redesign.

Funding History

21
Total raised:$21.5M
Grant$958K
Grant$987K
Grant$943K
Grant$931K

Opportunities

The growing need for pandemic preparedness and durable diagnostics for evolving pathogens presents a significant opportunity.
Aldatu's PANDAA technology is uniquely positioned to address the critical challenge of viral mutation in assay design, which could lead to widespread adoption in public health and clinical labs for outbreak response and routine monitoring of diseases like HIV.

Risk Factors

Key risks include the challenge of commercial adoption against entrenched PCR methods, the costly and uncertain regulatory pathway for diagnostic approvals, and intense competition from large, established diagnostics companies.
The company's focus on outbreak diseases also ties its market to unpredictable funding cycles and epidemic events.

Competitive Landscape

Aldatu competes in the molecular diagnostics space with large multinationals (e.g., Roche, Abbott, Thermo Fisher) that dominate the PCR market, as well as numerous startups. Its differentiation lies in the PANDAA platform's specific claim of variant resilience, a niche advantage in infectious disease testing that addresses a known pain point but must prove superior in cost, ease-of-use, and performance to gain market share.

More companies in Diagnostics & Precision Medicine →More companies in United States →